Aptinyx
Evanston
Illinois
United States
128 articles about Aptinyx
-
Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
10/25/2021
Aptinyx Inc. today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights.
-
Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors
10/20/2021
Aptinyx Inc. today announced the appointment of Gilmore O’Neill, M.B., M.M.Sc., to the company’s board of directors.
-
Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference
9/20/2021
Aptinyx Inc. today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m. ET.
-
Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures
9/16/2021
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures.
-
Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
8/31/2021
Aptinyx to Participate in H.C. Wainwright 23 rd Annual Global Investment Conference
-
Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights
8/10/2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the second quarter of 2021 and provided key business updates.
-
Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
8/3/2021
Aptinyx Inc. today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the “Brains of the Operation - Novel Approaches in Neuro” panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10 at 12:00 p.m. ET.
-
Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
7/26/2021
Aptinyx Inc. today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report second quarter 2021 financial results and discuss recent business highlights.
-
Aptinyx to Participate in William Blair Biotech Focus Conference 2021
7/12/2021
Aptinyx Inc. today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m. ET.
-
Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
7/6/2021
Aptinyx Inc. today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m. ET.
-
Aptinyx to Participate in Upcoming Investor Conferences - June 17, 2021
6/17/2021
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, announced that the Company will be participating in two upcoming investor conferences
-
Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder
6/15/2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that it has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD) after having received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration (FDA)
-
Aptinyx Reports First Quarter 2021 Financial Results and Highlights
5/13/2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2021 and highlighted recent progress across the company’s pipeline of novel, clinical-stage, NMDA receptor modulators.
-
Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors
5/10/2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company’s Board of Directors.
-
Aptinyx Presents Additional Positive Data from Phase 2 Exploratory Study of NYX-783 in PTSD at Society of Biological Psychiatry Annual Meeting
4/29/2021
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented additional data from its exploratory Phase 2 study of NYX-783 in patients with post-traumatic stress disorder (PTSD) at the Society of Biological Psychiatry (SOBP) Annual Meeting being held virtually April 29 - May 1, 2021.
-
Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
4/29/2021
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that the company will host a conference call and live webcast on Thursday, May 13, 2021 at 5:00 p.m. ET to report first quarter 2021 financial results and discuss recent business highlights.
-
Aptinyx to Participate in Upcoming Conferences
4/27/2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the Company will be participating in two upcoming conferences: 4 th Annual Neuroscience Innovation Forum – Norbert Riedel, Ph.D., chief executive officer, will participate in the Pain & Addiction Panel discussion at 11:30 a.m
-
Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies
4/6/2021
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson’s disease and dementia with Lewy bodies.
-
Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
3/24/2021
Phase 2 studies in fibromyalgia and painful DPN enrolling as planned – data readouts expected in 1H 2022 Phase 2 study in cognitive impairment expected to recommence imminently – data readout expected in 2H 2022 Reported data from Phase 2 exploratory study of NYX-783 in PTSD, supporting further clinical development – meeting with FDA to discuss future development path April 29, 2021
-
Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021
3/2/2021
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 24, 2021 at 5:00 p.m. ET to report fourth quarter and full year 2020 financial results